LAST UPDATED
May 6, 2024
Clinicaltrials.gov ID
CTSID
CTSID
A Phase 2, Double-Blinded, Randomized, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of GS-5290 in Participants With Moderately to Severely Active Ulcerative Colitis (PALEKONA)
The goal of this study is to learn if tilpisertib fosmecarbil (formerly known as GS-5290) is effective and safe in treating participants with moderate to severe ulcerative colitis. The study will compare participants in different treatment groups treated with tilpisertib fosmecarbil with participants treated with placebo. The primary objective of this study is to demonstrate the efficacy of tilpisertib fosmecarbil, compared to placebo control, in achieving Clinical Response at Week 12.
View MoreAge
18 Years - 75 Years
Sex
All
Healthy Volunteers
No
Medical Condition
Ulcerative Colitis
Gender
N/A
Date
December 2023 - June 2025
Study Type
Interventional
Study Phase
Phase 2
Product
Tilpisertib Fosmecarbil, Placebo
Sun City, Arizona, United States, 85351
Chula Vista, California, United States, 91910
Coronado, California, United States, 92118
Garden Grove, California, United States, 92845
Lancaster, California, United States, 93534
Lancaster, California, United States, 93534
Murrieta, California, United States, 92563
San Francisco, California, United States, 94115
Hollywood, Florida, United States, 33021
Largo, Florida, United States, 33771
Miami, Florida, United States, 33135
Naples, Florida, United States, 34102
Orlando, Florida, United States, 32807
Port Orange, Florida, United States, 32127
Wellington, Florida, United States, 33414
Decatur, Georgia, United States, 30033
Rochester, Minnesota, United States, 55905
Saint Louis, Missouri, United States, 63141
Brooklyn, New York, United States, 11215
Cincinnati, Ohio, United States, 45249
Mentor, Ohio, United States, 44060
Oklahoma City, Oklahoma, United States, 73134
Boerne, Texas, United States, 78006
El Paso, Texas, United States, 79936
Garland, Texas, United States, 75044
Houston, Texas, United States, 77074
Lubbock, Texas, United States, 79410
Mansfield, Texas, United States, 76063
San Antonio, Texas, United States, 78212
San Antonio, Texas, United States, 78229
South Brisbane, Queensland, Australia, 4101
Woolloongabba, Queensland, Australia, 4102
Woodville, South Australia, Australia, 5011
Clayton, Victoria, Australia, 3168
Vienna, Austria, 1090
London, Canada, N6A 5A5
Toronto, Canada, M2K 2W2
Vaughan, Canada, L4L 4Y7
Montpellier, France, 34295
Nantes, France, 44000
Toulouse, France, 31059
Liepzig, Germany, 4103
Budapest, Hungary, 1033
Milano, Italy, 20089
Rozzano, Italy, 20089
Minato-ku, Japan, 105-8471
Minato-ku, Japan, 108-8642
Mitaka-shi, Japan, 181-8611
Oita-shi, Japan, 870-0823
Sagaken, Japan, 849-8501
Sapporo, Japan, 060-8543
Seodaemun-Gu, VIC, Korea, Republic of, 3772
Busan, Korea, Republic of, 48108
Daegu, Korea, Republic of, 42415
Seoul, Korea, Republic of, 02447
Seoul, Korea, Republic of, 03181
Seoul, Korea, Republic of, 04763
Seoul, Korea, Republic of, 06351
Wonju, Korea, Republic of, 26426
Sopot, Poland, 81-756
Bern, Switzerland, 3012
Bury, United Kingdom, BL9 7TD
London, United Kingdom, E1 2AJ
Norwich, United Kingdom, NR4 7UZ
Southampton, United Kingdom, SO16 6YD
Share Trial